<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="sofosbuvir’s inhibitory effects on YFV replication: in a mouse model," exact="sofosbuvir" post="was able to decrease mortality and weight loss associated"/>
 <result pre="(mAb) therapies [44]. Antiviral mAbs represent viable therapeutic options, including" exact="palivizumab" post="(marketed as Synagis), which is licensed for use against"/>
 <result pre="feverAntivir. Res.20087811612410.1016/j.antiviral.2007.10.00918061688 34.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine)"/>
 <result pre="Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122"/>
 <result pre="in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122 37.YinZ.ChenY.-L.SchulW.WangQ.-Y.GuF.DuraiswamyJ.KondreddiR.R.NiyomrattanakitP.LakshminarayanaS.B.GohA.et al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc. Natl. Acad. Sci. USA2009106204352043910.1073/pnas.090701010619918064"/>
 <result pre="immature flavivirus particlesEMBO J.2003222604261310.1093/emboj/cdg27012773377 60.ReschB.Product review on the monoclonal antibody" exact="palivizumab" post="for prevention of respiratory syncytial virus infectionHum. Vaccin. Immunother.2017132138214910.1080/21645515.2017.133761428605249"/>
</results>
